Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites Clinical Trial

Official title:
A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites (OPTIONS-02)

Status Recruiting

Clinical Trial Summary

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory malignant ascites.

Clinical Trial Description

This study is to evaluate the safety, effectiveness of local immune activation, and efficiency in patients with refractory malignant ascites after Intraperitoneal injection of oncolytic Viruses H101 and Tislelizumab. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05303844
Study type	Interventional
Source	Fudan University
Contact	Peng Wang, MD
Phone	86-21-64175590
Email	peng_wang@fudan.edu.cn
Status	Recruiting
Phase	Phase 1
Start date	April 2, 2022
Completion date	March 20, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01852409` - Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites	Phase 1
Completed	`NCT04771676` - Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites	Phase 2
Withdrawn	`NCT02477657` - Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology
Completed	`NCT02891369` - Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites